RetinAI, Retina Consultants of America partner to build real-world database
- RetinAI and Retina Consultants of America will develop an AI-insight driven database.
- The database will include information on a variety of retinal diseases.
RetinAI Medical and Retina Consultants of America have partnered to build an artificial intelligence-driven real-world evidence database, according to a press release.
The U.S.-based database will combine information from Retina Consultants of America’s (RCA) 1.7 million patient visits across 200 nationwide locations with insights from RetinAI’s Discovery platform for biomarker analysis and predictive disease analytics.
“Through this partnership with RCA, we are revolutionizing the efficiency and robustness of making decisions around patient care, with an unprecedented scale of biomarker-driven insights from quality-driven, real-world data,” Carlos Ciller, PhD, CEO of RetinAI, said in the release. “This will enable an elevated level of target-based research and patient-centric care for continuous improvement to patient outcomes and the introduction of new precision-based medicines.”
Starting later this year, the database will include real-world data for retinal diseases, including age-related macular degeneration, diabetic macular edema and diabetic retinopathy, with plans to expand into cardiovascular and neurodegenerative areas in which retinal imaging can help identify disease.
“We’ve established the largest group of top-ranked retinal care and research practices in the U.S., and through this network and this collaboration with RetinAI, we want to unlock a deeper level of understanding of retinal diseases,” David M. Brown, MD, chairman of RCA’s medical leadership board, said in the release. “We are proud to partner with RetinAI in our mutual fight against blindness.”